ASRM Releases First Updated Guidance on Recurrent Pregnancy Loss in Over a Decade
New committee opinion emphasizes evidence-based evaluation, targeted care, emotional support during High-Risk Pregnancy Awareness Week
For Immediate Release
WASHINGTON, DC—As High-Risk Pregnancy Awareness Week (June 1–8, 2026) begins, the American Society for Reproductive Medicine (ASRM) is highlighting recurrent pregnancy loss as a serious and often misunderstood reproductive health condition through its newly updated Practice Committee opinion, the first update on the topic since 2012. The opinion outlines a more evidence-based approach to evaluation and care.
“Recurrent pregnancy loss can be medically complex, emotionally devastating, and deeply isolating for patients and families,” said Robert E. Brannigan, MD, President of ASRM. “This updated guidance reflects ASRM’s commitment to ensuring that patients receive care grounded in the best available science, delivered with compassion, and focused on what is most likely to help. Patients experiencing recurrent pregnancy loss deserve answers, support, and care that is guided by evidence.”
ASRM defines recurrent pregnancy loss (RPL) as the spontaneous loss of two or more pregnancies, excluding confirmed molar or ectopic pregnancies. The updated opinion also recognizes very early pregnancy losses confirmed by blood or urine testing and clarifies that losses do not need to be consecutive to warrant evaluation.
Key recommendations from the updated opinion include:
- Chromosome testing of miscarriage tissue, when possible, as a first step in evaluation
- More targeted testing and evaluation based on a patient’s history and risk factors
- Screening for conditions such as thyroid disease and diabetes when appropriate
- Avoiding routine use of tests and treatments that lack strong evidence of benefit
- Greater emphasis on emotional support and counseling for patients and couples
For patients and families navigating RPL, the updated opinion offers reassurance and hope: ASRM notes that 50 to 80 percent of patients will go on to have a successful pregnancy, even without medical intervention.
High-Risk Pregnancy Awareness Week is a national campaign focused on raising awareness of conditions that can complicate pregnancy and the importance of specialized care for patients and families navigating those experiences. As the week kicks off, ASRM encourages patients, clinicians, and policymakers to continue advancing compassionate, evidence-based care for those affected.
For almost a century, the American Society for Reproductive Medicine (ASRM) has been the global leader in multidisciplinary reproductive medicine research, ethical practice, and education. ASRM impacts reproductive care and science worldwide by creating funding opportunities for advancing reproduction research and discovery, by providing evidence-based education and public health information, and by advocating for reproductive health care professionals and the patients they serve. With members in more than 100 countries, the Society is headquartered in Washington, DC, with additional operations in Birmingham, AL. www.asrm.org
For media inquiries regarding this press release contact:
Sean Tipton
ASRM Chief Advocacy and Policy Officer
E: stipton@asrm.org
Anna Hovey
Advocacy Engagement Specialist
E: ahovey@asrm.org
J. Benjamin Younger Office of Public Affairs
726 7th St. SE
Washington, DC 20003
Tel: (202) 863-2494
Press Releases
Check out these press releases as well
ASRM Responds to Supreme Court Mifepristone Decision
ASRM supports continued access to mifepristone, warning that unnecessary restrictions could delay reproductive healthcare and harm patients.
ASRM Responds to Trump Administration’s Announcement Regarding Insurance for Fertility Care
ASRM responds to Trump IVF insurance proposal, urging broader fertility care access and public input on draft coverage rules.
New Research Examines Range of Restorative Reproductive Medicine Practices from Evidence-Based Perspective
ASRM’s Fertility and Sterility series examines restorative reproductive medicine, IVF alternatives, and evidence-based fertility care amid growing policy debate.